TickerLab QUANT ANALYTICS
Solutions
Zero Point Market Pulse Intraday Analyzer EOD Analyzer ApexQQuant

Market awaiting data
NIFTY — —
VIX — —
Policy & Macro
HDFC Bank shares fall as 3 US law firms launch probe o… Regulatory · yesterday DLF Phase 4 crackdown: DTCP seals 35 floors, warns Gur… Regulatory · 21 Jul Income tax dept places ₹4 cr penalty on Titan over und… IT Dept · 14 Jul
Last Shipped
Liquid Strikes goes live in Intraday Analyzer — the option-liquidity ranking now refreshes every 5 minutes during market hours, with Greeks 11 Jul
Account Pricing Support Coverage
Legal
Disclaimer Privacy Policy Terms of Service Refund Policy Grievance
Sign in Sign up

Max Pain in Nifty Options: The Logic, the Math, and the Limits: 25 Jul 2026 · 3 min read

Ask around any options desk in expiry week and someone will mention the
max pain level. It sounds ominous. It is actually just an arithmetic
exercise on the option chain — worth understanding precisely because so
many people quote it loosely.

The idea in one line

For every possible expiry price, you can compute how much money all option
buyers (calls and puts together) would collectively make or lose. Max
pain is the expiry price where option buyers collectively lose the most
—
equivalently, where option writers (sellers) keep the most premium.

The math, without tears

Take the option chain for one expiry. For each candidate settlement price S:

  1. Every call strike below S pays out (S − strike) × its open interest;
    calls above S expire worthless.
  2. Every put strike above S pays out (strike − S) × its open interest;
    puts below S expire worthless.
  3. Add the two: that is the total payout writers owe if expiry lands at S.

Repeat for every strike and you get a U-shaped curve — the pain curve.
Its minimum is the max pain strike: the settlement level at which the least
money flows from writers to buyers.

Why anyone believes expiry gravitates there

The theory: option writers are disproportionately professionals who hedge.
As expiry approaches, their hedging flows (and their incentive to defend
short-option positions) are said to nudge the underlying toward the level
where their books hurt least. When Nifty settles near the week's max pain
level, believers nod.

The honest limits

  • The number moves. Max pain is recomputed as OI shifts; the "target"
    quoted on Monday is often a different strike by Thursday. A moving target
    that gets revised toward price will always look prophetic in hindsight.
  • The evidence is mixed. Settlements land near max pain often enough to
    keep the idea alive and miss often enough to defeat anyone treating it as
    a rule. Trending markets in particular run straight past it.
  • Correlation has a boring explanation. High-OI strikes cluster where
    the market has already been trading; expiring near them is partly just
    expiring near where price already was.
  • It says nothing about path. Even a settlement at max pain says nothing
    about the week's swings on the way there.

The useful takeaway is smaller than the folklore: the pain curve is a
compact summary of where option money is committed across strikes. Read
as positioning context — heavy strikes, lopsided sides, day-to-day drift of
the minimum — it earns its place. Read as a prophecy, it does not.

Where to watch this live

Ticker Lab computes this for you, live: the Intraday Analyzer → F&O
mode → Max Pain sub-tab
renders the full pain curve for the selected
symbol and expiry — every strike's writer payout, with the minimum-pain
strike highlighted — beside the OI chain, PCR and ATM Greeks sub-tabs that
show the positioning behind the curve. You can watch the minimum drift as
open interest shifts through the week, which is precisely the honest way to
use the number: as moving context, never as a target.

Questions or a different read? Tell us on X
@tickerlabHQ — or through the Ideas board if
you're a member.

Informational, not advisory. Ticker Lab explains how market data is read;
it does not provide investment advice or trading calls.

Was this useful?

← All posts

Ticker Lab is an informational platform, not an advisory service. What we provide are directional market observations and data tooling — nothing here is investment advice, a recommendation, or a solicitation of any kind. Ticker Lab is not a SEBI-registered Investment Adviser or Research Analyst.

Disclaimer · Privacy Policy · Terms of Service · Refund Policy · Grievance · Coverage · Support

© 2026 Ticker Lab · All rights reserved · Contact: [email protected]